The Journal of Practical Medicine ›› 2026, Vol. 42 ›› Issue (14): 2577-2587.doi: 10.3969/j.issn.1006-5725.2026.14.011

• Treatise:Mechanism and Practice • Previous Articles    

piR-13663072 inhibits homocysteine-induced podocyte apoptosis via regulating the Bcl-2/Bax-Caspase-3 signaling pathway

Lianpeng YANG1,Ning DING2,Ziqing WANG1,3,Yining TIAN2,Yichen WANG2,Yideng JIANG2,Guanjun LU4()   

  1. 1.The First Clinical Medical College of Ningxia Medical University,Yinchuan 750004,Ningxia,China
    2.NHC Key Laboratory of Metabolic Cardiovascular Diseases Research,Ningxia Medical University,Yinchuan 750004,Ningxia,China
    3.The Second Surgical Department,Qinghai Provincial Hospital of Traditional Chinese Medicine,Xining 810000,Qinghai,China
    4.Department of Urology,Ningxia Medical University General Hospital,Yinchuan 750004,Ningxia,China
  • Received:2026-05-25 Online:2026-07-25 Published:2026-08-05
  • Contact: Guanjun LU E-mail:luguanjun566@163.com

Abstract:

Objective To investigate whether piR-13663072 inhibits homocysteine (Hcy)-induced apoptosis in mouse podocyte cell line-5 (MPC-5) by regulating the Bcl-2/Bax-Caspase-3 signaling pathway. Methods A hyperhomocysteinemia (HHcy)-induced kidney injury model was established using Cbs+/- mice, and RNA sequencing (RNA-seq) was employed to screen for differentially expressed piRNAs in kidney tissues. An in vitro podocyte injury model was created by treating MPC-5 cells with Hcy (80 μmol/L). The expression of piR-13663072 was verified by quantitative real-time PCR (qRT-PCR), and its species conservation was analyzed. An overexpression cell model was constructed through the transfection of cells with a piR-13663072 mimic. A silenced cell model was constructed via the transfection of cells with a piR-13663072 inhibitor. The expression levels of apoptosis-related proteins (Bax, Caspase-3, and Bcl-2) were detected via Western blot. The number of apoptotic cells was assessed by propidium iodide (PI) staining, and cytoskeletal morphology was observed using phalloidin staining. Results Hcy intervention notably induced apoptosis in MPC-5 cells (as evidenced by the elevated expressions of the pro-apoptotic proteins Bax and Caspase-3, and the reduced expression of the anti-apoptotic protein Bcl-2), accompanied by cytoskeletal disruption. RNA-seq and qRT-PCR validation demonstrated that piR-13663072 was significantly downregulated in both the kidneys of mice with HHcy-induced injury and Hcy-treated MPC-5 cells. Moreover, this piRNA exhibits moderate conservation among mammals. Following transfection with the piR-13663072 mimic, the expression level of piR-13663072 was significantly elevated. Overexpression of piR-13663072 suppressed the expressions of Bax and Caspase-3, promoted the expression of Bcl-2, effectively decreased the number of Hcy-induced PI-positive cells, and alleviated cytoskeletal damage. Conversely, transfection with the piR-13663072 inhibitor markedly decreased the level of piR-13663072, upregulated the expressions of Bax and Caspase-3, inhibited the expression of Bcl-2, further increased the number of Hcy-induced PI-positive cells, and exacerbated cytoskeletal damage. Conclusions The expression of piR-13663072 is down-regulated in Hcy-induced podocyte injury. Overexpression of piR-13663072 can effectively inhibit podocyte apoptosis and attenuate cytoskeletal damage through the regulation of the Bcl-2/Bax-Caspase-3 signaling pathway, thus exerting a protective effect on podocytes. In contrast, silencing of piR-13663072 aggravates the aforementioned injuries. Therefore, this molecule shows promise as a potential biomarker and therapeutic target for HHcy-induced kidney injury.

Key words: piRNA-13663072, homocysteine, chronic kidney disease, podocytes, apoptosis

CLC Number: